The Ministry of Health of the Russian Federation has issued a permit for trials of the FiloPan vaccine for the prevention of infections caused by Marburg and Ebola viruses, FV reports, referring to data from the State Register of Medicines (GRLS). Phase 1 of the clinical trial is intended to test the safety, tolerability, and immunogenicity of the drug in adult volunteers.
There are going to be 64 subjects in the trials. They will be held in four medical centers: A. A. Smorodintsev Research Institute of Influenza, I.M. Sechenov First Moscow State Medical University (Sechenov University), National Research Center Eko-bezopasnost and Infectious Clinical Hospital No. 1 Of the Moscow Department of Health. Phase 1 of the trial should be completed by the end of 2023.
According to the trial protocol, FiloPan is a two-component combined vector vaccine for the prevention of filovirus infections: Ebola virus disease and Marburg hemorrhagic fever. According to the registry of trials, this is the first permit for a trial of a vaccine against the Marburg virus disease. There are no registered therapies for Marburg virus disease.
